Source comparison
Peptides for Growth Hormone: Compound Comparison
GHRP-2 GHS-R1a (ghrelin receptor) ~20 minutes 100–200 mcg subcutaneous 5–8× Moderate (3–4 weeks continuous) Hexarelin GHS-R1a ~70 minutes 6–10× High (2–3 weeks continuous) Ipamorelin GHS-R1a (selective agonist) ~2 hours 200–300 mcg subcutaneous 3–5× Low (minim
This comparison does not assign a generated winner or score.
- GHRP-2
- GHS-R1a (ghrelin receptor)
- ~20 minutes
- 100–200 mcg subcutaneous
- 5–8×
- Moderate (3–4 weeks continuous)
- Hexarelin
- GHS-R1a
- ~70 minutes
- 6–10×
- High (2–3 weeks continuous)
- Ipamorelin
- GHS-R1a (selective agonist)
- ~2 hours
- 200–300 mcg subcutaneous
- 3–5×
- Low (minimal at 8+ weeks)
- CJC-1295 (with DAC)
- GHRH-R
- 6–8 days
- 2 mg once weekly subcutaneous
- 2–4× sustained elevation
- Very low
- Sermorelin
- ~10 minutes
- 200–500 mcg 2–3× daily
- 2–3×
- Low
- MK 677 (ibutamoren)
- GHS-R1a (oral agonist)
- 4–6 hours
- 10–25 mg oral daily
- 2–3× sustained
- Moderate (4–6 weeks)
- Hexarelin produces the highest peak GH response but also the fastest receptor desensitisation. Continuous daily dosing beyond three weeks shows attenuated response in 60–70% of research models. Ipamorelin's selectivity for GHS-R1a without secondary effects on cortisol or prolactin makes it the preferred choice for long-duration studies. CJC-1295's extended half-life eliminates the need for daily injections but produces sustained GH elevation rather than discrete pulses. This blunted pulsatility may reduce downstream IGF-1 production efficiency compared to compounds that preserve physiological pulse architecture.